BAYER WKN: BAY001 ISIN: DE000BAY0017 Kürzel: BAYN Forum: Aktien Thema: Hauptdiskussion
Auf flatexDEGIRO: BUZZ-Bristol Myers falls after Bayer stops late-stage study of new anti-clotting drug 12:37 20/11/2023 Shares of drugmaker Bristol Myers Squibb fall ~4% to $48.81 premarket Germany's Bayer on Sunday stopped a late-stage trial testing a new anti-clotting drug due to lack of efficacy Bayer's asundexian was shown to be inferior to BMY and Pfizer's established anticoagulant Eliquis in preventing strokes in patients with atrial fibrillation which is irregular heart rhythm In late-stage trial, BMY and Johnson & Johnson are jointly studying experimental drug milvexian, which also belongs to the class of drugs known as factor XIa inhibitor The failure of Bayer's trial will undoubtedly impact investor confidence in the ability of Factor XIa inhibitors to best Eliquis in atrial fibrillation, such as in the ongoing late-stage trial with milvexian - William Blair BMY's big-selling blood thinner Eliquis is also one of the 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program Up to last close, BMY stock down ~30% YTD (Reporting by Sriparna Roy in Bengaluru)
Auf flatexDEGIRO: BUZZ-Bristol Myers falls after Bayer stops late-stage study of new anti-clotting drug 12:37 20/11/2023 Shares of drugmaker Bristol Myers Squibb fall ~4% to $48.81 premarket Germany's Bayer on Sunday stopped a late-stage trial testing a new anti-clotting drug due to lack of efficacy Bayer's asundexian was shown to be inferior to BMY and Pfizer's established anticoagulant Eliquis in preventing strokes in patients with atrial fibrillation which is irregular heart rhythm In late-stage trial, BMY and Johnson & Johnson are jointly studying experimental drug milvexian, which also belongs to the class of drugs known as factor XIa inhibitor The failure of Bayer's trial will undoubtedly impact investor confidence in the ability of Factor XIa inhibitors to best Eliquis in atrial fibrillation, such as in the ongoing late-stage trial with milvexian - William Blair BMY's big-selling blood thinner Eliquis is also one of the 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program Up to last close, BMY stock down ~30% YTD (Reporting by Sriparna Roy in Bengaluru)
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | BAYER Hauptdiskussion | ||
| 2 | BAYER Insiderboard | ||
| 3 | Bayer, Livetrading mit Nachweis über Profilbild | ||
| 4 | Bayer neutrale Diskussion |
|
|
Thema | ||
|---|---|---|---|
| 1 | AMC ENTERTAINMENT Hauptdiskussion | -1,20 % | |
| 2 | NVIDIA Hauptdiskussion | +2,43 % | |
| 3 | 2G BIO-ENERGIETECHNIK Hauptdiskussion | +5,05 % | |
| 4 | CAMECO Hauptdiskussion | +1,01 % | |
| 5 | Vulcan Energy Resources Hauptdiskussion | -2,28 % | |
| 6 | ALBEMARLE Hauptdiskussion | -2,33 % | |
| 7 | AMERICAN LITHIUM Hauptdiskussion | +19,60 % | |
| 8 | Nikola Hauptforum | -1,40 % | |
| 9 | NEL ASA Hauptdiskussion | -2,70 % | |
| 10 | Dax Prognose | +0,77 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | AMC ENTERTAINMENT Hauptdiskussion | -1,20 % | |
| 2 | NVIDIA Hauptdiskussion | +2,43 % | |
| 3 | 2G BIO-ENERGIETECHNIK Hauptdiskussion | +5,05 % | |
| 4 | CAMECO Hauptdiskussion | +1,01 % | |
| 5 | Vulcan Energy Resources Hauptdiskussion | -2,28 % | |
| 6 | ALBEMARLE Hauptdiskussion | -2,33 % | |
| 7 | AMERICAN LITHIUM Hauptdiskussion | +19,60 % | |
| 8 | Nikola Hauptforum | -1,40 % | |
| 9 | NEL ASA Hauptdiskussion | -2,70 % | |
| 10 | Volt Resources Hauptdiskussion | +4,17 % | Alle Diskussionen |